

# Dr. Amit Kumar Mittal

PhD (Pharmaceutical Biotechnology) · MSc (Biotechnology)

Jodhpur, Rajasthan, India | +91-70148-42607 | +91-90234-38087  
amitkrbiotech@gmail.com

[LinkedIn](#) · [Google Scholar](#) · [ResearchGate](#)  
SCOPUS: 56740153300 · ORCID: 0000-0003-0604-4787

15+

Years Experience

42

Peer-reviewed  
Publications

5,400+

Citations

18

h-index

Top 2%

Stanford–Elsevier (2022 &  
2024)

## PROFESSIONAL SUMMARY

Senior research and medical communications professional with 10+ years spanning pharmaceutical biotechnology, HTA/HEOR, clinical/regulatory writing, and translational science. Currently Scientist D at AIIMS Jodhpur (DHR-funded HTA Resource Centre), leading systematic evidence synthesis, health economic modelling, and scientific publications for government and policy audiences. Recognised among Stanford–Elsevier World's Top 2% Scientists (2022 & 2024); h-index 18 with 5,400+ citations across 42 peer-reviewed publications. Deep expertise in pharmaceutical sciences, clinical research, evidence-based medicine, and cross-functional stakeholder communication — with a track record of delivering high-quality scientific output under regulatory and timeline pressures.

## CORE COMPETENCIES

- Systematic Literature Reviews (SLR/TLR)
- Scientific & Medical Writing
- Clinical/Regulatory Documentation
- Evidence Synthesis & Meta-analysis
- HTA & HEOR Research
- Health Economic Modelling (CEA/BIA)
- Manuscript Development & Publication
- PRISMA / CONSORT / CHEERS / ICH
- PubMed, Embase, Scopus, SciFinder
- EndNote, Zotero, Mendeley
- GraphPad Prism, SPSS, OriginPro
- Stakeholder & Policy Communication

## PROFESSIONAL EXPERIENCE

### Scientist D

May 2021 – Present

Resource Centre/Hub for Health Technology Assessment (RCHTA), AIIMS Jodhpur · Funded by Department of Health Research, Govt. of India

- Lead HTA and HEOR projects: cost-effectiveness analyses, budget impact analyses, health economic modelling, and evidence synthesis supporting national policy and reimbursement decisions.
- Design and execute systematic literature reviews and meta-analyses; apply PRISMA, CHEERS, and HTA-India standards to produce publication-ready outputs.
- Author technical reports, HTA dossiers, policy briefs, and peer-reviewed manuscripts communicated to government technical committees, state health departments, and multidisciplinary stakeholders.
- Manage project lifecycles end-to-end: protocol development, statistical analysis plans, cross-functional coordination with clinicians, statisticians, and epidemiologists.
- Contribute to national HTA capacity-building initiatives; organise workshops and participate in DHR, PGIMER, and ISHTA forums.

### Research Scientist & Medical Writer

Aug 2016 – May 2018

Pharmazz Inc., Greater Noida, India · Pharmaceutical R&D & Regulatory Affairs

- ▶ Led end-to-end regulatory and clinical medical writing across preclinical to Phase I–III development, ensuring compliance with ICH, GCP, and GLP standards.
- ▶ Authored key regulatory documents: Investigator's Brochures, study protocols, synopses, SOPs, CRFs, Informed Consent Documents, and Clinical Study Reports (CSRs).
- ▶ Managed IND/NDA submissions; maintained eCTD and Trial Master File (TMF) systems for streamlined regulatory processes.
- ▶ Coordinated cross-functional clinical operations, conducted literature searches and data analyses, and presented findings to regulatory authorities.

### Research Associate

May 2018 – May 2021

Amity Institute of Pharmacy, Amity University, Noida · DBT-Funded Project

- ▶ Contributed to DBT-funded translational research on smart hyaluronic acid–hydrogel systems for wound healing: study design, biomaterial characterisation, and experimental execution.
- ▶ Conducted SLRs, data analyses, and drafted peer-reviewed manuscripts, technical reports, and funding progress updates.

### Post-Doctoral Fellow

Feb 2015 – Feb 2016

Burnett School of Biomedical Sciences, University of Central Florida, USA · NIH-Funded

- ▶ Led NIH-supported research on oxidative stress, mitochondrial dysfunction, and aldehyde metabolism in cardiovascular diseases; published findings in peer-reviewed journals.

### Senior / Junior Research Fellow (PhD)

Jun 2009 – Dec 2014

NIPER, S.A.S. Nagar (Mohali) · CSIR-Funded

- ▶ Completed PhD on novel bionanomaterials for drug delivery; published in high-impact journals (Biotechnology Advances IF 17.6, Journal of Colloid and Interface Science IF 9.9).
- ▶ Presented at Indian Science Congress and International Nanotek & Expo (Las Vegas, USA); received International Travel Grant from DST, DBT, ICMR & CSIR.

## EDUCATION

**PhD, Pharmaceutical Technology (Biotechnology)** — NIPER Mohali (National Institute of Pharmaceutical Education & Research)

2014

*Thesis: "Development of novel bionanomaterials for drug delivery and therapeutic applications"*

**MSc, Biotechnology** — University of Rajasthan, Jaipur

2006

**BSc, Biosciences** — University of Rajasthan, Jaipur

2004

## HONOURS, AWARDS & FELLOWSHIPS

- ▶ **Stanford University–Elsevier World's Top 2% Scientists** — 2022 & 2024
- ▶ **GATE 2009:** 99.32 percentile, All India Rank 84 (MHRD, Govt. of India)
- ▶ **GATE 2008:** 96.42 percentile, All India Rank 477
- ▶ **CSIR–UGC JRF & NET:** Qualified (Dec 2007; Jun 2008; Jun 2009)
- ▶ **ICMR–JRF Fellowship:** Qualified (Jul 2008)
- ▶ **Rajasthan State Eligibility Test (SET):** Qualified, 2009
- ▶ **International Travel Grant (DST, DBT, ICMR & CSIR)** — 3rd International Conference on Nanotek & Expo, Las Vegas, USA (2013)

## KEY RESEARCH PROJECTS

- ▶ Cost-effectiveness of Risdiplam for Spinal Muscular Atrophy newborns — DHR, Govt. of India **[Ongoing]**
- ▶ RMNCAH+N service delivery costing at Ayushman Bharat HWCs (Multi-centric) — PGIMER & UNICEF **[Completed]**
- ▶ Cost-effectiveness of PMBJP (Jan Aushadhi) and Financial Risk Protection — PGIMER & DHR **[Completed]**

- ▶ Evaluation of Phase 2 in Drug-Resistant Epilepsy: HTA Perspective — DHR, Govt. of India [Completed]
- ▶ Cost-effectiveness of Venaseal™ for Varicose Vein Treatment — DHR, Govt. of India [Completed]
- ▶ Khamira Banafsha Lozenges for COVID-19 Prophylaxis (Co-PI) — CCRUM, Ministry of AYUSH — ₹9.95 Lakhs [Completed]
- ▶ Industry-Sponsored Diabetes Research & New Drug Documentation — Jagat Pharma Industry — ₹3.0 Lakhs [Completed]

## SELECTED PUBLICATIONS

42 peer-reviewed publications · 20 as first/corresponding author · 16 in Q1 journals · Cumulative IF: 140 · h-index: 18 · Citations: 5,400+

- ▶ **Mittal AK et al.** Economic Evidence on Cost-Effectiveness of Newborn Screening for SMA: Systematic Review. *European Journal of Pediatrics* (2025). IF 3.9, Q1
- ▶ **Mittal AK et al.** Presepsin vs nCD64 in Neonatal Sepsis: Systematic Review and Meta-analysis. *Clinical Epidemiology and Global Health* (2025). IF 2.3, Q2
- ▶ **Mittal AK & Banerjee UC.** In vivo toxicity and anticancer activity of biosynthesized metal nanoparticles. *Materials Today Communications* (2021). IF 3.7, Q1 · Citations: 22
- ▶ **Mittal AK et al.** Wound healing acceleration via polymeric hydrogel in diabetic rats. *ACS Omega* (2020). IF 4.1, Q1 · Citations: 47
- ▶ **Mittal AK, Chisti Y, Banerjee UC.** Synthesis of metallic nanoparticles for medicinal applications. *Biotechnology Advances* (2013). IF 17.7, Q1 · Citations: 3,286
- ▶ **Mittal AK et al.** Biosynthesis of silver nanoparticles: mechanism and therapeutic potential. *Journal of Colloid and Interface Science* (2014). IF 9.9, Q1 · Citations: 464
- ▶ **Bhaumik J, Mittal AK et al.** Applications of phototheranostic nanoagents in photodynamic therapy. *Nano Research* (2015). IF 10.3, Q1 · Citations: 115

Full publication list available on [Google Scholar](#) and [ResearchGate](#).

## BOOKS & BOOK CHAPTERS

- ▶ **Biochemistry and Clinical Pathology** (Co-author). Paging Publishers, 2020.
- ▶ **Current Status of NanoBioMaterials in Drug Delivery** in Therapeutic Nanostructures, Vol. 2. Elsevier, 2016. Citations: 26
- ▶ **Emerging Potential of CRISPR-Cas9 on Drug Discovery** in Animal Screening, Vol. 2. Paging Publishers, 2019.
- ▶ **Medicinally Important Flowers in Nanoparticle Synthesis** in Secondary Metabolites from Medicinal Plants. CRC Press (ISBN 9781003213727).

## CERTIFICATIONS & PROFESSIONAL DEVELOPMENT

- ▶ **Advanced Health Economics** — PGIMER Chandigarh (2025)
- ▶ **Health Technology Assessment** — DHR & PGIMER Chandigarh (2024)
- ▶ **Basic Health Economics** — PGIMER Chandigarh (2023)
- ▶ **Economic Evaluation in Public Health** — University of Washington (2021)
- ▶ **Health Economics Modelling & Costing Workshops** — DHR/PGIMER/ISHTA (2021–2025)

## TECHNICAL SKILLS

Literature Databases	PubMed, Embase, Scopus, ScienceDirect, SciFinder, Web of Science, Cochrane Library
Reference Management	EndNote, Zotero, Mendeley
Statistical & Analysis	SPSS, GraphPad Prism, SigmaPlot, OriginPro, R Studio, Stata, Pass, Revman, Treeage, etc

<b>Writing Standards</b>	PRISMA, CONSORT, STROBE, CHEERS, ICH E6/E3, GCP/GLP, Rayyan/Covidence
<b>Document Types</b>	SLR/TLR reports, manuscripts, CSRs, IBs, protocols, policy briefs, executive summaries
<b>Lab Techniques</b>	HPLC, LC-MS, PCR/qPCR, ELISA, HTS, Western blot, flow cytometry, DLS, EM, cell culture
<b>Office &amp; Design</b>	Microsoft Word, Excel, PowerPoint; Canva; Adobe Creative Suite,

## EDITORIAL & PEER REVIEW ACTIVITY

Peer reviewer for 10+ international journals including: *Nanomedicine*, *Current Nanoscience*, *Journal of Nanoparticle Research*, *PLoS ONE*, *Materials Science & Engineering: C*, *Global Journal of Nanomedicine*, *Frontiers in Nanoscience & Nanotechnology*.

## REFERENCES

Available on request.

*I hereby declare that all information provided is accurate to the best of my knowledge.*

Place: Jodhpur, Rajasthan, India | Date: May 21, 2026

**Dr. Amit Kumar Mittal**